Verrica Pharmaceuticals Inc (VRCA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.09-10.69%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · VRCA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | |
|---|---|---|---|
| Revenues | |||
| Revenues | 30.3 | 35.6 | 7.6 |
| Total Revenues | 30.3 | 35.6 | — |
| Cost of Revenues | — | — | 2.6 |
| Operating Expenses & Income | |||
| Selling, General & Admin | 37.9 | 35.2 | 58.8 |
| R&D Expenses | 14.6 | 8.9 | 11.8 |
| Operating Income | (28.4) | (12.2) | (65.9) |
| Earnings from Continuing Operations | |||
| Interest Expense | — | 7.7 | 9.4 |
| Interest & Investment Income | 0.7 | 0.9 | 1.4 |
| Other Non-Operating Income / Expenses | (2.8) | (5.7) | (10.7) |
| Net Income | |||
| Net Income | (31.2) | (17.9) | (76.6) |
| Per Share | |||
| Basic EPS | (1.46) | (1.68) | (1.48) |
| Diluted EPS | (1.46) | (1.68) | (1.48) |
| Revenue per Share | 1.42 | — | — |
| Basic Weighted Avg Shares | 21.3 | 10.7 | 51.8 |
| Diluted Weighted Avg Shares | 21.3 | 10.7 | 51.8 |
| Supplemental | |||
| EBIT | (28.4) | (12.2) | (65.9) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.